{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:37:51Z","timestamp":1789558671015,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research Vice Chancellor of Tabriz University of Medical Sciences, IRAN"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-025-07214-2","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T18:00:45Z","timestamp":1753984845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Naimeh","family":"Mesri Alamdari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Barghaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Roshanravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Mobasseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helda","family":"Tutunchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Baharami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Aliasgarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahideh","family":"Sadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"7214_CR1","unstructured":"Atlas D. International diabetes federation. IDF Diabetes Atlas, 7th edn Brussels, Belgium: International Diabetes Federation. 2015;33(2)."},{"issue":"39","key":"7214_CR2","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"ATF Members","year":"2013","unstructured":"Members ATF, Ryd\u00e9n L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and developed in collaboration with the European association for the study of diabetes (EASD). Eur Heart J. 2013;34(39):3035\u201387.","journal-title":"Eur Heart J"},{"key":"7214_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-020-05350-5","volume":"13","author":"E Matin","year":"2020","unstructured":"Matin E, Ghaffari S, Garjani A, Roshanravan N, Matin S, Mesri Alamdari N, Safaie N. Oxidative stress and its association with ST resolution and clinical outcome measures in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. BMC Res Notes. 2020;13:1\u20136.","journal-title":"BMC Res Notes"},{"issue":"1\u2013S","key":"7214_CR4","first-page":"330e6","volume":"20","author":"N Roshanravan","year":"2018","unstructured":"Roshanravan N, Tarighat-Esfanjani A, Alamdari NM, Kheirouri S, Mousavi R, Alizadeh M. The effects of zinc supplementation on inflammatory parameters in pregnant women with impaired glucose tolerance: a randomized placebo controlled clinical trial. Prog Nutr. 2018;20(1\u2013S):330e6.","journal-title":"Prog Nutr"},{"issue":"12","key":"7214_CR5","doi-asserted-by":"publisher","first-page":"e13493","DOI":"10.1111\/jfbc.13493","volume":"44","author":"P Irandoost","year":"2020","unstructured":"Irandoost P, Mesri Alamdari N, Saidpour A, Shidfar F, Roshanravan N, Asghari Jafarabadi M, et al. The effects of Royal jelly and tocotrienol-rich fraction on impaired glycemic control and inflammation through Irisin in obese rats. J Food Biochem. 2020;44(12):e13493.","journal-title":"J Food Biochem"},{"issue":"7533","key":"7214_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","volume":"332","author":"R Huxley","year":"2006","unstructured":"Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73\u20138.","journal-title":"BMJ"},{"issue":"2","key":"7214_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.108.191305","volume":"119","author":"JS Skyler","year":"2009","unstructured":"Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American diabetes association and a scientific statement of the American college of cardiology foundation and the American heart association. Circulation. 2009;119(2):351\u20137.","journal-title":"Circulation"},{"issue":"1","key":"7214_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2015;38(1):140\u20139.","journal-title":"Diabetes Care"},{"issue":"3","key":"7214_CR9","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/ptr.6897","volume":"35","author":"P Irandoost","year":"2021","unstructured":"Irandoost P, Lotfi Yagin N, Namazi N, Keshtkar A, Farsi F, Mesri Alamdari N, Vafa M. The effect of capsaicinoids or capsinoids in red pepper on thermogenesis in healthy adults: A systematic review and meta-analysis. Phytother Res. 2021;35(3):1358\u201377.","journal-title":"Phytother Res"},{"issue":"22","key":"7214_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"key":"7214_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"M Roden","year":"2015","unstructured":"Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:1\u201311.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"7214_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.34172\/hpp.42486","volume":"14","author":"M Najafipour","year":"2024","unstructured":"Najafipour M, Najafipour F, Ostadrahimi A, Ghavami M, Razaghi Z, Tutunchi H, Alamdari NM. The effects of empagliflozin in patients with type 1 diabetes: results of a 12-week, double-blind, randomized, placebo-controlled clinical trial. Health Promotion Perspect. 2024;14(4):380\u20137.","journal-title":"Health Promotion Perspect"},{"issue":"14","key":"7214_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"7214_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.diabres.2015.05.025","volume":"109","author":"BM Mishriky","year":"2015","unstructured":"Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to Metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2015;109(2):378\u201388.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"7214_CR15","doi-asserted-by":"publisher","first-page":"BSR20190980","DOI":"10.1042\/BSR20190980","volume":"39","author":"D-k Zeng","year":"2019","unstructured":"Zeng D-k, Xiao Q, Li F-q, Tang Y-z, Jia C-l. Tang X-w. Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus. Biosci Rep. 2019;39(7):BSR20190980.","journal-title":"Biosci Rep"},{"key":"7214_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.diabres.2018.04.012","volume":"140","author":"F-S Yen","year":"2018","unstructured":"Yen F-S, Chiang J-H, Pan C-W, Lin BJ, Wei JC-C, Hsu C-C. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy. Diabetes Res Clin Pract. 2018;140:279\u201387.","journal-title":"Diabetes Res Clin Pract"},{"key":"7214_CR17","doi-asserted-by":"crossref","unstructured":"Talebi SS, Rezaie S, Hajmiri MS, Zamanirafe M, Ranjbar A, Moridi H et al. Comparison of the effects of empagliflozin and sitagliptin, as add-on to Metformin, on serum levels of Asprosin and metabolic parameters in patients with type 2 diabetes mellitus. Naunyn Schmiedebergs Arch Pharmacol. 2024:1\u201317.","DOI":"10.1007\/s00210-024-03219-z"},{"key":"7214_CR18","doi-asserted-by":"crossref","unstructured":"Zakaraia H, Salem H, Mostafa M, Ali A, Rabea H. Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial. European Review for Medical & Pharmacological Sciences. 2023;27(15).","DOI":"10.1186\/s43088-023-00442-0"},{"key":"7214_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","volume":"49","author":"MJ Hanley","year":"2010","unstructured":"Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71\u201387.","journal-title":"Clin Pharmacokinet"},{"key":"7214_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2165\/00003088-200342130-00001","volume":"42","author":"RZ Harris","year":"2003","unstructured":"Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 2003;42:1071\u201388.","journal-title":"Clin Pharmacokinet"},{"key":"7214_CR21","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1007\/s13300-021-01176-x","volume":"12","author":"D Ito","year":"2021","unstructured":"Ito D, Inoue K, Saito D, Hamaguchi K, Kaneko K, Sumita T, et al. Effects of Dapagliflozin compared with sitagliptin and Metformin in drug-na\u00efve Japanese patients with type 2 diabetes: a 12-week, open-label, randomized, active-controlled trial. Diabetes Therapy. 2021;12:3201\u201315.","journal-title":"Diabetes Therapy"},{"issue":"3","key":"7214_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"7214_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1464-5491.2009.02696.x","volume":"26","author":"A Hauber","year":"2009","unstructured":"Hauber A, Mohamed A, Johnson F, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416\u201324.","journal-title":"Diabet Med"},{"issue":"5","key":"7214_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1185\/03007995.2012.681639","volume":"28","author":"A Lund","year":"2012","unstructured":"Lund A, Knop FK. Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on Metformin and\/or sulphonylurea. Curr Med Res Opin. 2012;28(5):731\u20136.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"7214_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-13-102","volume":"13","author":"B Zinman","year":"2014","unstructured":"Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME\u2122). Cardiovasc Diabetol. 2014;13(1):1\u20138.","journal-title":"Cardiovasc Diabetol"},{"key":"7214_CR26","doi-asserted-by":"crossref","unstructured":"Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug design, development and therapy. 2014:1380-.","DOI":"10.2147\/DDDT.S50773"},{"issue":"10","key":"7214_CR27","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1111\/dom.13801","volume":"21","author":"YD Halvorsen","year":"2019","unstructured":"Halvorsen YD, Lock JP, Zhou W, Zhu F, Freeman MW. A 24-week, randomized, double\u2010blind, active\u2010controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to Metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metabolism. 2019;21(10):2248\u201356.","journal-title":"Diabetes Obes Metabolism"},{"issue":"S 01","key":"7214_CR28","doi-asserted-by":"publisher","first-page":"P142","DOI":"10.1055\/s-0034-1374999","volume":"9","author":"T Hach","year":"2014","unstructured":"Hach T, Gerich J, Salsali A, Kim G, Hantel S, Woerle H, Broedl U. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. Diabetol Und Stoffwechsel. 2014;9(S 01):P142.","journal-title":"Diabetol Und Stoffwechsel"},{"key":"7214_CR29","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.jcjd.2013.08.089","volume":"37","author":"I Tikkanen","year":"2013","unstructured":"Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension. Can J Diabetes. 2013;37:S30.","journal-title":"Can J Diabetes"},{"key":"7214_CR30","doi-asserted-by":"crossref","unstructured":"Stenl\u00f6f K, Cefalu W, Kim KA, Alba M, Usiskin K, Tong C et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity and Metabolism. 2013;15(4):372\u2013\u200982.","DOI":"10.1111\/dom.12054"},{"issue":"10","key":"7214_CR31","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc10-0612","volume":"33","author":"E Ferrannini","year":"2010","unstructured":"Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217\u201324.","journal-title":"Diabetes Care"},{"issue":"12","key":"7214_CR32","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/dom.12185","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Seman L, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle H. Efficacy and safety of Empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to Metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metabolism. 2013;15(12):1154\u201360.","journal-title":"Diabetes Obes Metabolism"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07214-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-025-07214-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07214-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:22:27Z","timestamp":1757326947000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-025-07214-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7214"],"URL":"https:\/\/doi.org\/10.1186\/s13104-025-07214-2","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was reviewed and approved by the Ethics Committee of Tabriz University of Medical Sciences (Ethical code: IR.TBZMED.REC.1398.850). Moreover, the study was performed by the Helsinki Declaration of 1964, and its later amendments; and all subjects provided informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"339"}}